Reportedly receiving the first Current Procedural Terminology (CPT) III code from the American Medical Association (AMA) for artificial intelligence (AI)-enabled brain magnetic resonance imaging (MRI) software, Icometrix says its adjunctive quantification software can be utilized for diagnosis and assessment of conditions ranging from Alzheimer’s disease and epilepsy to stroke and dementia.
Creating a potential path for reimbursement, the American Medical Association (AMA) has issued a Current Procedural Terminology (CPT) III code for the use of icometrix’s artificial intelligence (AI)-powered brain magnetic resonance imaging (MRI) quantification software.
Icometrix, which has five Food and Drug Administration (FDA)-cleared AI software applications for brain MRI and computed tomography (CT), said the CPT III code is the first one issued for adjunctive AI quantification of brain MRI scans.
“Precision medicine is vital for improving treatment of neurological conditions, and especially for multiple sclerosis,” noted Tim Coetzee, PhD, the chief advocacy, services, and science officer at the National Multiple Sclerosis Society. “This recognition creates a path for icometrix’s innovative technology to be integrated into the management of multiple sclerosis (MS) and takes us one step closer to a future where precision medicine guides treatment decisions.”
Icobrain ms, one of the aforementioned AI software applications, facilitates objective quantification and tracking of white matter hyperintensities on FLAIR, TI MRI and contrast-enhanced T1 MRI, according to icometrix. The company added that its portfolio of AI-enabled neuroimaging software can be utilized in the diagnosis and assessment of treatment for conditions ranging from Alzheimer’s disease and MS to stroke and epilepsy.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.